Table 2.
CGM metrics
| First trimester | Second trimester | Third trimester | Postpartum | |||||
|---|---|---|---|---|---|---|---|---|
| Women with RYGB | Matched control group | Women with RYGB | Matched control group | Women with RYGB | Matched control group | Women with RYGB | Matched control group | |
| Participants, n | 23 | 23 | 23 | 23 | 22 | 23 | 22 | 22 |
| Timing of CGM, weeks+days | 14+4 (13+6–15+3) | 14+3 (13+6–15+4) | 24+5 (24+1–25+5) | 24+4 (24+0–26+0) | 34+1 (32+3–35+4) | 34+3 (34+0–35+4) | 5+0 (4+2–5+4) | 5+0 (4+4–5+4) |
| Days CGM worn on each occasion | 8.4 (7.5–8.8) | 8.6 (7.8–8.7) | 8.0 (6.6–8.7) | 8.7 (8.4–8.8) | 8.4 (6.6–8.7) | 8.7 (7.0–8.7) | 7.6 (6.9–8.7) | 8.7 (8.3–8.7) |
| Active CGM time, % | 97 (93–100) | 100 (97–100) | 98 (92–100) | 100 (97–100) | 97 (94–100) | 100 (99–100) | 90 (86–99) | 100 (97–100) |
| Mean glucose level, mmol/L | 5.8 (5.3–6.1) | 5.9 (5.5–6.2) | 5.4 (5.2–5.9) | 5.7 (5.3–6.0) | 5.6 (5.3–5.9) | 5.8 (5.4–6.5) | 6.0 (5.4–6.5) | 6.0 (5.7–6.7) |
| Glycemic variability (coefficient of variation) | 25 (20–28) | 14 (13–16) | 27 (22–31) | 15 (14–17) | 26 (23–30) | 16 (15–19) | 23 (19–26) | 13 (11–15) |
| Proportion of time, mean (SD) | ||||||||
| Above target (>7.8 mmol/L) | 9.0 (5.1) | 3.6 (3.9) | 9.5 (5.4) | 3.8 (4.8) | 9.4 (5.9) | 5.8 (6.0) | 11.6 (6.7) | 6.6 (8.8) |
| In target (3.5–7.8 mmol/L) | 89.5 (5.0) | 96.1 (3.7) | 87.3 (6.4) | 95.9 (4.7) | 87.5 (6.5) | 93.5 (5.7) | 87.5 (6.4) | 93.3 (8.7) |
| Below target (<3.5 mmol/L) | 1.5 (2.5) | 0.3 (0.7) | 3.1 (4.5) | 0.3 (0.3) | 3.0 (4.9) | 0.8 (1.6) | 0.8 (1.1) | 0.1 (0.2) |
| Very low (<3.0 mmol/L) | 0.6 (1.1) | 0.0 (0.0) | 1.0 (1.4) | 0.0 (0.1) | 1.1 (2.3) | 0.2 (0.5) | 0.3 (0.4) | 0.0 (0.0) |
| Participants with increased time, n (%) | ||||||||
| Below target (4%) | 4 (17) | 0 (0) | 6 (26) | 0 (0) | 4 (18) | 2 (9) | 1 (5) | 0 (0) |
| Very low (1%) | 5 (22) | 0 (0) | 6 (26) | 0 (0) | 4 (18) | 1 (4) | 1 (5) | 0 (0) |
Data are presented as median (IQR) unless otherwise indicated. Significant differences are in bold.